Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (thymic myoid cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: atracurium, vecuronium, suxamethonium +18 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 86 | 0.91 |
| pathways Reactome | 1 pathway; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 10880
Sealed predictions
- CHRND in dopamine neurons, braak-0.50 (p 0.173) → +0.18 (p 0.639)receipt 10886
Swarm cases
receipt 10886: CHRND in dopamine neurons, braak
- power
- full sample -0.34 (p 0.161, n 18), 95% CI -0.70 to +0.15. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.36 (p 0.148, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.039, n 18). not the mix.
- skeptic
- leave-one-out range -0.45 to -0.26, sign flips 0; without severely affected donors -0.34 (p 0.161, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CHRND in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts